Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. New York University Langone Medical Center, New York, NY, United States



Survival: 14.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: New York University Langone Medical Center
   
Journal: Link
   
Date: 3/2011

Description:
Patients:
This study involved 111 patients with peripheral T-cell lymphoma (a subtype of non-Hodgkin’s lymphoma). The average patient age was 57.7 years and 68% were male.

Treatment:
Patients were treated with the biologic therapy agent pralatrexate, which is an inhibitor of a protein (dihydrofolate reductase) involved in cell growth.

Toxicities:
There was one treatment-related death due to cardiopulmonary arrest (heart attack). Grade 4 mucositis (inflammation of the lining of the mouth and digestive tract), thrombocytopenia, and neutropenia were also reported.

Results:
The median overall survival was 14.5 months.

Support:
Several of the authors were supported or employed by Allos Therapeutics, Inc., the makers of pralatrexate.

Correspondence: Dr. Owen A.O’Connor; email: owen.o’connor@nyumc.org

E-mail to a Friend Email Physician More Information